The study of markers of endothelial dysfunction in metabolic syndrome
-
Ashok Kumar Ahirwar
,
Anju Jain
Abstract
Background: Metabolic syndrome (MetS) consists of a constellation of metabolic abnormalities that confer increased risk of cardiovascular disease (CVD) and diabetes mellitus (DM). Endothelial dysfunction is one of the key components of MetS which is caused by imbalance between vasodilatory substances like nitric oxide (NO) and vaso-constrictive substances like endothelin and prothrombotic factors like plasminogen activator inhibitor-1 (PAI-1).
Objective: To study the markers of endothelial dysfunction (NO and endothelin) and prothrombotic markers (PAI-1) among the study subjects.
Materials and methods: We enrolled 50 diagnosed cases of MetS as per International Diabetes Federation (IDF) criteria and 50 healthy volunteers as controls. Clinical evaluation included anthropometric, routine biochemical, hematological, serum insulin, NO, endothelin and PAI-1 measurements.
Results: Subjects with MetS had higher insulin, endothelin and PAI-1 levels and low NO levels as compared to controls and the difference was found to be significant. The serum insulin levels were positively correlated with PAI-1 and endothelin, and negatively correlated with NO.
Conclusion: Endothelial functional status as reflected by decreased NO and increased serum endothelin levels along with insulin resistance is seen in MetS. Moreover, higher serum level of PAI-1 also tilts towards a more prothrombotic milieu in the vascular endothelium. Hence endothelial dysfunction and prothrombotic markers may be used to guide for early diagnosis of cardiovascular disease and type 2 diabetes in patients with MetS.
Acknowledgments
Special thanks to Dr. Surjeet Kumar Patra, Dr. Shilpa Bharadwaj, Dr. Rajni Mahajan and the technician staff of the Department of Biochemistry, Lady Hardinge Medical College, New Delhi.
Conflict of interest statement: The authors declared no conflict of interest.
References
1. Ahirwar AK, Jain A, Goswami B, Bhatnagar MK, Bhatacharjee J. Imbalance between protective (adiponectin) and prothrombotic (Plasminogen Activator Inhibitor-1) adipokines in metabolic syndrome. Diab Met Syndr: Clin Res Rev 2014;8:152–5.10.1016/j.dsx.2014.04.035Search in Google Scholar
2. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 2011;18:139–43.10.1097/MED.0b013e3283444b09Search in Google Scholar
3. Grazyna S. Pro-inflammatory and prothrombotic factors and metabolic syndrome. eJIFCC 2007,18 (1) [Cited 2011 sep 19] Available from: http://www.ifcc.org/index.asp?cat=Publications&scat=eJIFCC_&suba=Vol_18_No_1&subx=Proinflammatory%20and%20prothrombotic%20Factors%20and%20Metabolic%20Sndrome%20&zip=1&dove=1&zona=full&numero=&aq=1.Search in Google Scholar
4. Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation 2004;109:2–4.10.1161/01.CIR.0000110642.73995.BFSearch in Google Scholar
5. Sarafidis PA, Bakris GL. Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 2007;92:379–85.10.1210/jc.2006-1819Search in Google Scholar
6. Alessi MC,Vague IJ. PAI-1 and the Metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200–7.10.1161/01.ATV.0000242905.41404.68Search in Google Scholar
7. Duvnjak L, Duvnjak M. The metabolic syndrome – an ongoing story. J Physiol Pharmacol 2009;60:19–24.Search in Google Scholar
8. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.10.2337/diacare.23.1.57Search in Google Scholar
9. Mathew F, Glenda J, Jack L. Quantification of nitric and nitrate in extracellular fluids. Metho Enzymol 1996;268:237–46.10.1016/S0076-6879(96)68026-4Search in Google Scholar
10. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607.10.2337/diab.37.12.1595Search in Google Scholar PubMed
11. Sun YX, Hu SJ, Zhang XH, Sun J, Zhu CH, Zhang ZJ. Plasma levels of vWF and NO in patients with metabolic syndrome and their relationship with metabolic disorders. Zhejiang Da Xue Xue Bao Yi Xue Ban 2006;35:315–8.Search in Google Scholar
12. Cai H, Harrison DG, Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 2000;87:840–4.10.1161/01.RES.87.10.840Search in Google Scholar
13. Donatelli M, Hoffmann E, Colletti I, Andolina G, Russo V, Bucalo ML, Valenti TM, Compagno V, Cataldo MG, Morici ML. Circulating endothelin- 1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetol 1996;33: 246–8.10.1007/BF02048552Search in Google Scholar PubMed
14. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. American Diabetes Association. Diabetes 2007;56:728–34.10.2337/db06-1406Search in Google Scholar
15. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250–3.10.1016/0026-0495(86)90209-XSearch in Google Scholar
16. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996;97:37–46.10.1172/JCI118404Search in Google Scholar
17. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006;30:1308–14.10.1038/sj.ijo.0803189Search in Google Scholar
18. Chou YY, Sheu WH, Tang YJ, Chen YM, Liao SC, Chuang YW, Lin CS, Chen DY. Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan. Arch Gerontol Geriatr 2009;49(Suppl 2):41–5.10.1016/S0167-4943(09)70012-3Search in Google Scholar
©2015 by De Gruyter
Articles in the same Issue
- Frontmatter
- Original Articles
- Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA
- The study of markers of endothelial dysfunction in metabolic syndrome
- Steroid hormone secretion in inflammatory breast cancer cell lines
Articles in the same Issue
- Frontmatter
- Original Articles
- Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA
- The study of markers of endothelial dysfunction in metabolic syndrome
- Steroid hormone secretion in inflammatory breast cancer cell lines
